USTR Jamieson Greer has initiated a Section 301 investigation against Germany over alleged persistent underpayment for innovative pharmaceutical products. The investigation will determine whether Germany’s pricing practices are unreasonable or discriminatory and burden or restrict U.S. commerce. This is a formal trade action under the Trade Act of 1974 that could lead to retaliatory tariffs or other measures.
Official NewsUstrUnited States
USTR Initiates Section 301 Investigation into Germany’s Pharmaceutical Pricing Practices
Original: USTR Announces Initiation of Section 301 Investigation of Germany’s Persistent Underpayment for Innovative Pharmaceutical Products